IL-25 as a potential therapeutic target in allergic asthma

ImmunotherapyVol. 7, No. 6 CommentaryIL-25 as a potential therapeutic target in allergic asthmaMartin D Knolle, Batika M Rana & Andrew NJ McKenzieMartin D Knolle*Author for correspondence: E-mail Address: mknolle@mrc-lmb.cam.ac.uk Division of Protein & Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, UK Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UKSearch for more papers by this author, Batika M Rana Division of Protein & Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, UKSearch for more papers by this author & Andrew NJ McKenzie Division of Protein & Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, UKSearch for more papers by this authorPublished Online:23 Jun 2015https://doi.org/10.2217/imt.15.36AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: allergyasthmainnate lymphoid cellsinterleukin-25viral exacerbationReferences1 Licona-Limon P, Kim LK, Palm NW, Flavell RA. Th2, allergy and group 2 innate lymphoid cells. Nat. Immunol. 14(6), 536–542 (2013).Crossref, Medline, CAS, Google Scholar2 Fort MM, Cheung J, Yen D et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15(6), 985–995 (2001).Crossref, Medline, CAS, Google Scholar3 Lee J, Ho WH, Maruoka M et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276(2), 1660–1664 (2001).Crossref, Medline, CAS, Google Scholar4 Ballantyne SJ, Barlow JL, Jolin HE et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120(6), 1324–1331 (2007).Crossref, Medline, CAS, Google Scholar5 Petersen BC, Budelsky AL, Baptist AP, Schaller MA, Lukacs NW. Interleukin-25 induces type 2 cytokine production in a steroid-resistant interleukin-17RB+ myeloid population that exacerbates asthmatic pathology. Nat. Med. 18(5), 751–758 (2012).Crossref, Medline, CAS, Google Scholar6 Barlow JL, Flynn RJ, Ballantyne SJ, Mckenzie AN. Reciprocal expression of IL-25 and IL-17A is important for allergic airways hyperreactivity. Clin. Exp. Allergy 41(10), 1447–1455 (2011).Crossref, Medline, CAS, Google Scholar7 Salimi M, Barlow JL, Saunders SP et al. A role for IL-25 and IL-33-driven Type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210(13), 2939–2950 (2013).Crossref, Medline, CAS, Google Scholar8 Walker JA, Barlow JL, Mckenzie AN. Innate lymphoid cells – how did we miss them? Nat. Rev. Immunol. 13(2), 75–87 (2013).Crossref, Medline, CAS, Google Scholar9 Hams E, Armstrong ME, Barlow JL et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl Acad. Sci. USA 111(1), 367–372 (2014).Crossref, Medline, CAS, Google Scholar10 Gregory LG, Jones CP, Walker SA et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 68(1), 82–90 (2013).Crossref, Medline, Google Scholar11 Wang YH, Angkasekwinai P, Lu N et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204(8), 1837–1847 (2007).Crossref, Medline, CAS, Google Scholar12 Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL-9 expression by IL-25 signaling. Nat. Immunol. 11(3), 250–256 (2010).Crossref, Medline, CAS, Google Scholar13 Shin HW, Kim DK, Park MH et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J. Allergy Clin. Immunol. pii:S0091-6749(15)00074-3 (2015) (Epub ahead of print).Crossref, Google Scholar14 Kouzaki H, Tojima I, Kita H, Shimizu T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 49(5), 741–750 (2013).Crossref, Medline, CAS, Google Scholar15 Cheng D, Xue Z, Yi L et al. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am. J. Respir. Crit. Care Med. 190(6), 639–648 (2014).Crossref, Medline, Google Scholar16 Beale J, Jayaraman A, Jackson DJ et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med. 6(256), 256ra134 (2014).Crossref, Medline, Google Scholar17 Lloyd CM, Saglani S. Epithelial cytokines and pulmonary allergic inflammation. Curr. Opin. Immunol. 34C, 52–58 (2015).Crossref, Google Scholar18 Gauvreau GM, O'Byrne PM, Boulet LP et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370(22), 2102–2110 (2014).Crossref, Medline, Google Scholar19 Moffatt MF, Gut IG, Demenais F et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363(13), 1211–1221 (2010).Crossref, Medline, CAS, Google Scholar20 Barlow JL, Peel S, Fox J et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132(4), 933–941 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByIL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production31 October 2018 | Immunology and Cell Biology, Vol. 97, No. 2Biological Properties and the Role of IL-25 in Disease PathogenesisJournal of Immunology Research, Vol. 2018Cytokine-targeting biologics for allergic diseasesAnnals of Allergy, Asthma & Immunology, Vol. 120, No. 4Group 2 ILCs: A way of enhancing immune protection against human helminths?12 July 2017 | Parasite Immunology, Vol. 40, No. 2Inflammation factors in hepatoblastoma and their clinical significance as diagnostic and prognostic biomarkersJournal of Pediatric Surgery, Vol. 52, No. 9Modeling T H 2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma28 June 2017 | Immunological Reviews, Vol. 278, No. 1The epithelial barrier and immunoglobulin A system in allergy21 October 2016 | Clinical & Experimental Allergy, Vol. 46, No. 11Year in review 2015: Asthma and chronic obstructive pulmonary disease29 March 2016 | Respirology, Vol. 21, No. 4Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 171 February 2016 | British Journal of Pharmacology, Vol. 173, No. 5 Vol. 7, No. 6 Follow us on social media for the latest updates Metrics Downloaded 153 times History Published online 23 June 2015 Published in print July 2015 Information© Future Medicine LtdKeywordsallergyasthmainnate lymphoid cellsinterleukin-25viral exacerbationFinancial & competing interests disclosureA McKenzie has a financial interest in the development of an anti-IL-25 antibody licensed to Centocor Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download